A carregar...
Cognitive evolution in natalizumab-treated multiple sclerosis patients
BACKGROUND: Cognitive dysfunction affects up to 65% of multiple sclerosis (MS) patients and progresses over time. Natalizumab has been shown to be superior to placebo in preserving cognition for the first two years of therapy. OBJECTIVES: The objectives of this study are to understand the impact of...
Na minha lista:
| Publicado no: | Mult Scler J Exp Transl Clin |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5408753/ https://ncbi.nlm.nih.gov/pubmed/28607732 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217316657116 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|